These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 19900074)
21. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico. Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192 [TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Bergeron C; Largeron N; McAllister R; Mathevet P; Remy V Int J Technol Assess Health Care; 2008; 24(1):10-9. PubMed ID: 18218164 [TBL] [Abstract][Full Text] [Related]
23. Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea. Lee H; Hur S; Jang H; Lee IH; Sohn WY; Van Kriekinge G; Kim BG Asian Pac J Cancer Prev; 2019 Feb; 20(2):425-435. PubMed ID: 30803204 [TBL] [Abstract][Full Text] [Related]
24. The cost-effectiveness of male HPV vaccination in the United States. Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193 [TBL] [Abstract][Full Text] [Related]
25. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Sinanovic E; Moodley J; Barone MA; Mall S; Cleary S; Harries J Vaccine; 2009 Oct; 27(44):6196-202. PubMed ID: 19698807 [TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. Obradovic M; Mrhar A; Kos M Eur J Public Health; 2010 Aug; 20(4):415-21. PubMed ID: 20624834 [TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras. Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157 [TBL] [Abstract][Full Text] [Related]
28. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Coupé VM; van Ginkel J; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J Int J Cancer; 2009 Feb; 124(4):970-8. PubMed ID: 19035448 [TBL] [Abstract][Full Text] [Related]
29. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients. Wong G; Howard K; Webster A; Chapman JR; Craig JC Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131 [TBL] [Abstract][Full Text] [Related]
30. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Schiffman M Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850 [TBL] [Abstract][Full Text] [Related]
31. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049 [TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Olsen J; Jepsen MR Int J Technol Assess Health Care; 2010 Apr; 26(2):183-91. PubMed ID: 20392322 [TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence. Li X; Stander MP; Van Kriekinge G; Demarteau N BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918 [TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand. Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710 [TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore. Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579 [TBL] [Abstract][Full Text] [Related]
36. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149 [TBL] [Abstract][Full Text] [Related]
37. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Dee A; Howell F Eur J Public Health; 2010 Apr; 20(2):213-9. PubMed ID: 19864366 [TBL] [Abstract][Full Text] [Related]
38. Cost-benefit analysis on the HPV vaccine in Medicaid-enrolled females of the Appalachian region of Kentucky. Prasad SR; Hill R J Ky Med Assoc; 2008 Jun; 106(6):271-6. PubMed ID: 18630037 [TBL] [Abstract][Full Text] [Related]
39. [Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in The Netherlands]. de Kok IM; Habbema JD; Mourits MJ; Coebergh JW; van Leeuwen FE Ned Tijdschr Geneeskd; 2008 Sep; 152(37):2001-4. PubMed ID: 18825885 [TBL] [Abstract][Full Text] [Related]
40. A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy. Favato G; Baio G; Capone A; Marcellusi A; Saverio Mennini F Clin Ther; 2013 Jul; 35(7):904-14. PubMed ID: 23806328 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]